Can Fite Biofarma (Can Fite Biofarma) EV-to-EBITDA

: -0.18 (As of Today)

View and export this data going back to 2012. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Can Fite Biofarma's enterprise value is $1.47 Mil. Can Fite Biofarma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.20 Mil. Therefore, Can Fite Biofarma's EV-to-EBITDA for today is -0.18.

The historical rank and industry rank for Can Fite Biofarma's EV-to-EBITDA or its related term are showing as below:

CANF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.47 Med: -2.03 Max: 0.56
Current: -0.18

During the past 13 years, the highest EV-to-EBITDA of Can Fite Biofarma was 0.56. The lowest was -9.47. And the median was -2.03.

CANF's EV-to-EBITDA is ranked worse than
100% of 470 companies
in the Biotechnology industry
Industry Median: 9.07 vs CANF: -0.18

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Can Fite Biofarma's stock price is $1.97. Can Fite Biofarma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.000. Therefore, Can Fite Biofarma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Can Fite Biofarma EV-to-EBITDA Historical Data

The historical data trend for Can Fite Biofarma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

-0.76

-1.14

-0.99

-1.01

-0.44

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA																-1.01	0.32	-0.30	-0.30	-0.44

Competitive Comparison

For the Biotechnology subindustry, Can Fite Biofarma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma EV-to-EBITDA Distribution

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's EV-to-EBITDA falls into.

Can Fite Biofarma EV-to-EBITDA Calculation

Can Fite Biofarma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	1.474	/	-8.195
	=	-0.18

Can Fite Biofarma's current Enterprise Value is $1.47 Mil.
Can Fite Biofarma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.20 Mil.

Can Fite Biofarma (AMEX:CANF) EV-to-EBITDA Explanation

Can Fite Biofarma's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	1.97	/	-3.000
	=	At Loss

Can Fite Biofarma's share price for today is $1.97.
Can Fite Biofarma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.000.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Can Fite Biofarma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).